Biomarkers of outcome from cardiovascular disease
- 1 October 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 12 (5) , 412-419
- https://doi.org/10.1097/01.ccx.0000244119.16377.75
Abstract
Recognition of the fact that low-grade local and systemic inflammation accompanies all stages of atherogenesis has led to the identification of a number of novel biomarkers of cardiovascular risk. We highlight recent epidemiological and experimental evidence concerning four emerging biomarkers: C-reactive protein, interleukin-6, D-dimer and white blood cell count. Recent epidemiological and experimental data on C-reactive protein, the most extensively studied marker of systemic inflammation, produced in the liver in response to interleukin-6, has cast some doubt on its clinical utility and causal involvement in atherogenesis. However, a large number of studies still strongly support C-reactive protein as an independent predictor of future cardiovascular risk and a potent proatherogenic agent. Among all markers of inflammation studied to date, C-reactive protein seems the most suitable one for use in clinical practice. Regarding white blood cell count, recent studies focused on the differential leucocyte count in coronary-heart-disease risk assessment; neutrophil count represents the strongest predictor of incident coronary heart disease. Thus, screening for low-grade inflammation using several novel biomarkers might provide an important tool to identify individuals at increased risk who would benefit most from targeted preventive interventions.Keywords
This publication has 57 references indexed in Scilit:
- C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Lipopolysaccharide (LPS) Contamination Plays the Real Role in C-Reactive Protein–Induced IL-6 Secretion From Human Endothelial Cells In VitroArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and LipopolysaccharideArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient miceProceedings of the National Academy of Sciences, 2005
- Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in HumansCirculation Research, 2005
- C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial PreparationsArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient MiceCirculation, 2004
- Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cellsBiochemical and Biophysical Research Communications, 2004
- Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic MiceCirculation, 2003
- Varied Biologic Functions of C-reactive Protein: Lessons Learned from Transgenic MiceImmunologic Research, 2002